{
    "clinical_study": {
        "@rank": "157930", 
        "arm_group": {
            "arm_group_label": "Canagliflozin + oral contraceptive", 
            "arm_group_type": "Experimental", 
            "description": "Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate whether there is a drug-drug interaction between\n      multiple doses of canagliflozin (JNJ-28431754) and single doses of an oral contraceptive\n      containing ethinyl estradiol and levonorgestrel.  The safety and tolerability of\n      canagliflozin will also be assessed in healthy volunteers."
        }, 
        "brief_title": "A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study will be an open-label (all volunteers and study staff know the identity of the\n      assigned treatment), single-center, fixed-sequence study (all volunteers receive the same\n      medication on the same days), to determine how canagliflozin (a drug currently being\n      investigated for the treatment of type 2 diabetes mellitus) affects the pharmacokinetics\n      (ie, how the body affects the drug) of an oral contraceptive containing ethinyl estradiol\n      and levonorgestrel. The study will consist of 3 phases; a screening phase, an open-label\n      treatment phase, and an end-of-study (or follow-up) phase. Each volunteer will participate\n      in the study for approximately 33 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Volunteer must have a body mass index (weight [kg]/height [m2]) between 18 and 30\n             kg/m2 (inclusive), and body weight not less than 50 kg\n\n          -  Volunteer must be a non-smoker (has not used tobacco or nicotine products in 6\n             months)\n\n        Exclusion Criteria:\n\n          -  History of or currently active illness considered to be clinically significant by the\n             Investigator or any other illness that the Investigator considers should exclude the\n             patient from the study or that could interfere with the interpretation of the study\n             results\n\n          -  History of, or presence of, disorders commonly accepted as contraindications to sex\n             hormonal therapy and contraindications to therapy with combined oral contraceptives\n\n          -  Volunteer has used, or is currently using, any hormonal contraceptive within 30 days\n             of admission to the study center or has received Depo Provera (or other combined\n             contraceptive injection or hormonal contraceptive implant) in the 6 months prior to\n             screening\n\n          -  Volunteer is breast-feeding"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714193", 
            "org_study_id": "CR014755", 
            "secondary_id": "28431754DIA1002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Canagliflozin + oral contraceptive", 
                "description": "One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.", 
                "intervention_name": "Oral contraceptive", 
                "intervention_type": "Drug", 
                "other_name": "Levora"
            }, 
            {
                "arm_group_label": "Canagliflozin + oral contraceptive", 
                "description": "One 200 mg tablet taken orally (by mouth) on Days 4 through 9.", 
                "intervention_name": "Canagliflozin (JNJ-28431754)", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-28431754"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Levonorgestrel", 
                "Contraceptives, Oral", 
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Ethinyl Estradiol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Canagliflozin (JNJ-28431754)", 
            "Pharmacokinetics", 
            "Contraceptives, Oral", 
            "Ethinyl Estradiol", 
            "Levonorgestrel", 
            "LEVORA"
        ], 
        "lastchanged_date": "November 16, 2012", 
        "number_of_arms": "1", 
        "official_title": "An Open-label Drug-Drug Interaction Study in Healthy Female Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
            "last_name": "Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Comparison of plasma concentrations of ethinyl estradiol and levonorgestrel, before and after administration of multiple doses of canagliflozin (JNJ-28431754). This will be used to determine whether there is a pharmacokinetic interaction between multiple doses of canagliflozin and single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel.", 
            "measure": "Plasma concentrations of ethinyl estradiol and levonorgestrel", 
            "safety_issue": "No", 
            "time_frame": "Up to Day 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714193"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Comparison of plasma concentrations of canagliflozin (JNJ-28431754) before and after administration of a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel. This will be used to determine whether there is a pharmacokinetic interaction between multiple doses of canagliflozin and single doses of an oral contraceptive containing ethinyl estradiol and levonorgestrel.", 
            "measure": "Plasma concentrations of canagliflozin (JNJ-28431754)", 
            "safety_issue": "No", 
            "time_frame": "Days 8 and 9"
        }, 
        "source": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2008", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}